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Abstract
Alzheimer disease (AD) is a neurodegenerative disorder characterized pathologically by the accumulation of
amyloid-beta (Aβ) plaques and tau neurofibrillary tangles (NFTs). Recently, primary age-related tauopathy (PART) has
been described as a new anatomopathological disorder where NFTs are the main feature in the absence of neuritic
plaques. However, since PART has mainly been studied in post-mortem patient brains, not much is known about
the clinical or neuroimaging characteristics of PART. Here, we studied the clinical brain imaging characteristics of
PART focusing on neuroanatomical vulnerability by applying a previously validated multiregion visual atrophy scale.
We analysed 26 cases with confirmed PART with paired clinical magnetic resonance imaging (MRI) acquisitions. In
this selected cohort we found that upon correcting for the effect of age, there is increased atrophy in the medial
temporal region with increasing Braak staging (r = 0.3937, p = 0.0466). Upon controlling for Braak staging effect,
predominantly two regions, anterior temporal (r = 0.3638, p = 0.0677) and medial temporal (r = 0.3836, p = 0.053),
show a trend for increased atrophy with increasing age. Moreover, anterior temporal lobe atrophy was associated
with decreased semantic memory/language (r = − 0.5823, p = 0.0056; and r = − 0.6371, p = 0.0019, respectively), as
was medial temporal lobe atrophy (r = − 0.4445, p = 0.0435). Overall, these findings support that PART is associated
with medial temporal lobe atrophy and predominantly affects semantic memory/language. These findings highlight
that other factors associated with aging and beyond NFTs could be involved in PART pathophysiology.
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Introduction
Degenerative dementias share the common feature of
protein misfolding in the brain, resulting in a defining
dementia-type abnormal protein with typical topo-
graphic deposition. One such example is the accumula-
tion of neurofibrillary tangles (NFTs), composed of
hyperphosphorylated tau protein, on a subgroup of
neurodegenerative diseases termed tauopathies [14].
Alzheimer disease (AD) is the most studied tauopathy;
in this particular case, another hallmark is the presence
of extracellular amyloid-beta (Aβ) plaques and brain
atrophy of specific regions, such as the medial temporal
lobe [14]. Following several brain autopsy studies
[28, 29] from which AD-indistinguishable NFTs were
found in the absence of Aβ plaques, the term pri-
mary age-related tauopathy (PART) was proposed for
this group of patients [10].
The pathological diagnosis of PART requires the pres-
ence of tau positive NFT with a Braak stage ≤ IV, with
minimal deposition beyond medial temporal lobes, and
with sparse (“possible PART”) to absent (“definite
PART”) Aβ deposition [10]. Concomitantly, PART can
be clinically classified as “asymptomatic” (without cogni-
tive deterioration or dementia) or “symptomatic” (with
cognitive deterioration or dementia) [16]. Since PART is
essentially a histological designation, there is a need for
further studies to advance in vivo diagnostic tools to
effectively differentiate it from AD, which could also lead
to better selection of patients for clinical trials. Therefore,
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neuropsychological evaluation, cerebrospinal fluid bio-
markers assessment and brain magnetic resonance im-
aging (MRI) are important tools to consider in the
characterization of PART.
To clinically differentiate PART from AD, previous
studies assessed the relationship between clinical and
neuropathologic features. It was observed that Braak sta-
ging was associated with an increased odds of having
cognitive impairment [7], but comparing to AD, patients
with PART were shown to have relative sparing of se-
mantic memory/language [9]. Moreover, it was shown
that episodic memory is relatively spared in patients with
the moderately severe stratum with a Clinical Dementia
Rating (CDR®) of 0.5–1, and attention is relatively spared
in the most severe stratum with CDR of 2–3 [9]. Consistent
findings were described in a clinical-imaging-pathological
study that showed that aggregated tau distribution was as-
sociated with poorer cognitive performance in “definite”
PART patients [20]. Moreover, a recent study showed that
autopsy confirmed PART cases with mild cognitive impair-
ment or dementia were clinically diagnosed with AD
greater than 50% of the time [30]. Therefore, there is a clin-
ical necessity of ante-mortem criteria for the effective diag-
nosis of PART, for instance, using brain MRI. To date, only
one study compared the in vivo brain MRI to neuropatho-
logical findings in patients with “definite” PART, which
found an association between Braak staging and atrophy of
the left head of the hippocampus [20]. Also, it described an
antero-posterior gradient of the hippocampus, with relative
sparing of the posterior portion, a finding that significantly
correlated with the preservation of episodic memories on
neuropsychological tests [20]. However, no systematic im-
aging interpretation method to efficiently use in a clinical
setting was proposed.
Therefore, the main goal of our study was to compare
in vivo brain MRI findings with neuropathological find-
ings at time of autopsy for people with “definite” PART
pathology. Specifically we used previously validated vis-
ual atrophy scales that evaluate six different brain re-
gions [13] to assess the potential link of NFT with
typical brain imaging pathological patterns, controlling
for either Braak staging or age. Moreover, we inquired
which neuropsychological domains were specifically cor-
related with atrophy in the affected brain regions.
Materials and methods
Participants
Cross-sectional data from the National Alzheimer’s
Coordinating Center’s (NACC) Uniform Data Set (UDS)
and Neuropathology Data Set (NP) were used. Data con-
tributed to NACC, including demographic, neuropsycho-
logical, clinical, and diagnostic data on participants with
normal cognition, mild cognitive impairment, and demen-
tia, were collected since 2005 from approximately 30 past
and present Alzheimer's Disease Centers (ADC) in
the United States. The UDS and NP data have been
meticulously described [4, 5, 8, 23]. We used data
collected between September 2005 and March 2018.
All participants provided written informed consent at
each ADC.
Selection criteria
From the total number of UDS participants as of the
March 2018 data freeze (n = 37,568), only those with
neuropathological data (n = 5135), most specifically
neuritic plaque (NP) data (n = 5110) were enrolled. We
excluded participants: (a) with neuropathological evidence
of frontotemporal lobar degeneration, Lewy bodies, amyo-
trophic lateral sclerosis, prion disease, or argyrophilic
grains; (b) with clinical evidence of dementia with Lewy
bodies, Parkinson disease, Down syndrome, Huntington
disease, prion disease, corticobasal degeneration, or pro-
gressive supranuclear palsy. With the application of these
exclusion criteria, 2350 participants remained. Consider-
ing only those with “definite” PART (defined as no NP –
n = 394) and availability of MRI scans, 33 participants
were considered. Five patients with other lesions that
biased volumetric interpretation (e.g., brain tumors) were
excluded. Two patients less than 40 years old were ex-
cluded, in order to obtain a more homogeneous cohort in
terms of age. Therefore, our cohort was composed of 26
patients.
Neuropathology data
Neuropathological data was collected by the ADCs by
using a standardized Neuropathology Form on UDS pa-
tients who died and consented to autopsy and neuropath-
ologic examination. Details on brain tissue preparation
and staining within the NACC NP dataset have been pre-
viously described [8]. This data was used to establish the
participants with “definite” PART, and to obtain the Braak
stage for neurofibrillary degeneration.
Brain MRI data
MR imaging examinations were performed mostly on
1.5 T or 3 T scanners, both from Philips®, Siemens® or
GE® manufacturers. Several imaging protocols were used
by the different centres; we always used T1-weighted
sequences in order to establish the degree of brain at-
rophy – spin-echo (SE) or magnetization-prepared
rapid gradient-echo (MPRAGE) sequences.
Image analysis
We used a group of validated MRI visual rating scales
[13] in order to assess brain atrophy on the following
regions: anterior cingulate, orbito-frontal, anterior tem-
poral, fronto-insular, medial temporal, and posterior re-
gions. Briefly, as previously described by the simplified
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version of these scales: orbito-frontal and anterior cingu-
late regions were rated on the first anterior slice where
the corpus callosum becomes visible, both from “0–3”,
where “0” is representing no atrophy; the fronto-insular
was rated over three slices, starting on the first anterior
slice where the anterior cingulate becomes visible and
moving posteriorly, from “0–3”; the anterior temporal
was rated at the level of the temporal pole, just anterior
to where the “temporal stem” connects the frontal and
temporal lobes, from “0–4”; the medial temporal was
rated according to the medial temporal lobe atrophy
(MTA) score – performed on the hippocampus at the
level of the anterior pons, from “0–4”; the posterior re-
gion was rated according to the four-point posterior at-
rophy scale described by Koedam, from “0–3” [21] –
overall score based on the presence of atrophy in sagittal
(widening of the posterior cingulate and parieto-
occipital sulcus, and atrophy of the precuneus on left
and right by considering paramedian sagittal images),
axial (widening of the posterior cingulate sulcus and sul-
cal dilatation in parietal lobes on axial images) and cor-
onal (widening of the posterior cingulate sulcus and
parietal lobes on coronal images) orientations, assessed
for left and right separately [13]. Two independent clas-
sifiers with neuroradiology experience were responsible
for rating the images. For each brain region scale, an
average of both hemispheres was considered and an
average of both classifiers was used. In this specific co-
hort no significant asymmetric atrophy was observed
(Additional file 1: Figure S1). In order to aid the rating
process, reference images for each rating scale were
provided to the classifiers based on Harper et al. [13]. At-
rophy classification data is summarized in Additional file 1:
Table S1. For Fig. 4, scale values were then converted to
percentage values, from 0%, as no atrophy, to 100%, as
maximal atrophy value considered for each scale. Images
were visualized in Horos® imaging software version 3.0.1.
Neuropsychological data
Several tests of memory, executive function, language
and processing speed were considered in our analysis.
Executive function was assessed by the Trail Making
Test (TMT) A and B, which globally tests attention, vis-
ual scanning and search skills, and psychomotor speed
and coordination [26]; TMT A can independently assess
processing speed, while TMT B assesses set switching;
on both parts of this test (i.e., A and B), the total num-
ber of seconds to complete the test, the number of com-
mission errors, and number of correct lines were
recorded; the Wechsler Adult Intelligence Scale digit
symbol test was also considered to provide an estimate
of processing speed [31]. Semantic memory/language
was assessed by category (vegetables and animals) verbal
fluency [22], consisting of a test on registering the total
number of vegetables and animals named in 60 s; the
Boston naming test [11], which also assesses the effect of
language function, more precisely the confrontational
word retrieval, was included in this evaluation, and con-
sisted of showing pictures (up to 60) to the patient, and
wait up to 20 s for the patients to name them. Attention
and working memory was evaluated by Digit span for-
wards and backwards test [18], consisting on registering
the ability of recalling a sequence of numbers shown,
and the total length of numbers successfully achieved.
Episodic memory was assessed by Current Logical
Memory 1A Story Units Recalled [1], for the total num-
ber of items recalled. Mini-Mental State Examination
[12] was performed as a brief cognitive screening instru-
ment that provides a measure of global cognition. Con-
cerning the data used for this study, the average delay
between MRI and neuropsychological data acquisition
was 2.7 years. All valid and available neuropsychological
data retrieved from NACC concerning the PART popu-
lation under study was included for analysis and is sum-
marized in Additional files 1: Table S2.
Statistical analysis
In order to assess the rating acuity, Spearman’s correlation
coefficient was calculated for the pair of classifiers per each
region and it was confirmed that there was a statistically
significant association between both (Additional file 1:
Table S3). Residuals were calculated for brain regional atro-
phy scores controlling for either age or Braak staging. These
were then plotted independently to Braak staging and age,
respectively. Regional brain atrophy scores were also plot-
ted for each of neuropsychological test considered and only
significant associations were represented. Pearson correl-
ation coefficients were calculated (r) and statistically signifi-
cant values were considered for p < 0.05. SPSS® Statistics
version 25, and GraphPad® Software version 8.0.0 were used
for all analyses.
Results
Twenty-six participants were considered for this study.
Table 1 summarizes the demographic characteristics of
the enrolled participants. Of the 26 “definite” PART pa-
tients, 17 (65.4%) were male. The mean age at the time
of MRI examination was 80.6 years (range: 51–99), and
the mean age of death was 83.5 years (range: 51–101).
The mean Braak stage was 1.5 (range: 0–4).
In this specific cohort, even though there was no sig-
nificant correlation between age and Braak stage (r = −
0.03079, p = 0.8813) (Fig. 1a) the majority of cases had
some degree of regional atrophy (Fig. 1b), and no signifi-
cant changes were observed between men and women
(Additional files 1: Figure S2). Upon correction for age,
the relative percentage of atrophy of the medial temporal
lobe significantly correlated with Braak staging (r =
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0.3937; p = 0.0466) (Fig. 2e). No statistically significant
results of regional brain atrophy were found for the
other regions evaluated (Fig. 2). Upon correction for
Braak staging, we observed a trend to increasing atrophy
with age, predominantly on the anterior temporal (r =
0.3638, p = 0.0677) (Fig. 3c) and medial temporal (r =
0.3836, p = 0.053) regions (Fig. 3e). Moreover, when we
compared cases Braak ≤1 with Braak ≥2 we observed
significant increased atrophy score in the medial tem-
poral region (Additional file 1: Figure S3).
From the 26 cases, the majority of them also per-
formed an extensive neuropsychological battery testing.
Considering this sample, we checked for an association
between regional brain atrophy and performance in each
of the cognitive domains assessed. We observed that
atrophy of the anterior temporal lobe was associated
with decreased semantic memory/language, given by
the animals and vegetables naming tests (r = − 0.5823,
p = 0.0056; and r = − 0.6371, p = 0.0019, respectively)
(Fig. 4a, b), as was atrophy of the medial temporal
lobe, given by the vegetables naming test (r = −
0.4445, p = 0.0435) (Fig. 4c).
Discussion
The main goal of this study was to compare the in vivo
brain MRI findings to neuropathological findings at aut-
opsy for patients identified with “definite” PART path-
ology. More specifically, we assessed the effects of Braak
staging and age on PART brain imaging associated atro-
phy patterns and its potential implications for specific
neuropsychological deficits. Our results showed an asso-
ciation between Braak staging and atrophy of the medial
temporal lobe on “definite” PART patients (i.e., brains
without neuritic plaques) upon correction for age. This
main finding was consistent with one described by an-
other imaging study, on which left hippocampal volume
was found to be decreased in PART [20]. It is also
consistent with previous anatomopathological studies
describing PART, where NFTs accumulation is pre-
dominantly confined to the temporal lobe [10]. Im-
portantly, medial temporal lobe atrophy is commonly
found in typical AD, namely with decreased hippo-
campal volume [25]. While at the imaging level this
observation does not help completely to distinguish
PART from early stage AD, it might distinguish it
from more advanced cases of AD where atrophy is
extensive in other brain regions. Given the sparsity of
PART patients with Braak stages III and IV, this is an
assumption future studies with more patients on these
advanced stages should address.
Our findings partly explain why many PART cases
identified post-mortem were clinically diagnosed as AD
[30]. The combination of other features, such as neuro-
psychological specific presentation, CSF signatures or
PET could lead to a more fine-tuned distinction between
PART and AD.
Various other observations support PART as a separate
pathological entity: the absence of an association between
PART and APOE ε4 allele, the strongest risk factor for
AD [3, 15]; “ghost” tangles, i.e. extracellular tangles, are
more frequently found in PART than AD patients [17];
and patients diagnosed with PART are frequently in the
8th–9th decades, as was found in our study, making it
highly improbable that Aβ deposition would only start
Table 1 Demographic characteristics of definite PART patients
PART population (N = 26)
Age MRI 80.6 (51–99)
Age of death 83.5 (51–101)
Difference age MRI to death 2.96 (1–7)




The table shows the summarized demographic characteristics of a cohort of
26 anatomopathological confirmed PART cases. Age MRI is the subject age
when brain imaging acquisition was performed and is reported in years as a
continuous variable with average, minimum and maximum values represented.
Age of death is reported in years as a continuous variable with mean, minimum
and maximum values represented. Braak stage is represented as categorical
values based on an anatomopathological validated staging scale with mean,
minimum and maximum values represented. Sex is differentially represented as
male and female with frequency and relative percent values for each










p = 0.8813 
r = -0.03079 
a
b
Fig. 1 Distribution of cases from a definite PART cohort based on
age and Braak staging. a Age in years is represented based on age
of death of the subjects. Braak staging is represented as categorical
values based on an anatomopathological validated staging scale. b
Representative case of a 78 year-old male from the PART cohort.
Axial, sagittal and coronal MRI T1-weighed images are shown
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then [20]. In fact, our results support the hypothesis of
PART being a form of pathological brain aging, with pref-
erential atrophy in the medial temporal lobes.
After controlling for Braak staging, our observations indi-
cate that, in this selected cohort, aging leads to a higher de-
gree of atrophy with predominance over the anterior and
medial temporal lobe regions – a fact that is consistent with
previous reported effects of aging [27]. One hypothesis is
that other neuropathological factors associated with aging
and beyond NFTs could be contributing to this regional
temporal atrophy, one possibility being transactive response
DNA-binding protein 43 (TDP-43). Interestingly, a recently
described neuropathologic entity, limbic-predominant age-
related TDP-43 encephalopathy (LATE), which is char-
acterized by TDP-43 accumulation in the limbic
system, can also present with dementia symptoms and
brain atrophy, with potential involvement of the tem-
poral lobe [24]. Remarkably, not only was TDP-43
pathology associated with greater atrophy in the med-
ial temporal lobe regions in PART cases [19], but also
independently of other neuropathological conditions
[6]. Therefore, future studies should address the inde-
pendent or cumulative impact of Aβ, tau and TDP-43
on brain regional atrophy, using AD, PART and
LATE cohorts. Even though major vascular lesions
were excluded after clinical neuroradiologist assess-
ment, it is still possible that finer microvascular
lesions, which are partially identified as white matter
T2 hyperintensities, could be another potential con-
tributing factor addressed in future studies.





































































































































































































p = 0.0466 
r = 0.3937 
p = 0.8485 
r = -0.03939 
p = 0.4603 
r = 0.1514 
p = 0.8012 
r = -0.05189 
p = 0.8448 
r = 0.04037 
p = 0.1110 
r = 0.3200 
Fig. 2 Medial temporal lobe atrophy correlates with increasing Braak staging. The values represented are residuals corrected for age, with
Pearson correlation analysis between Braak staging and atrophy of different brain regions based on a previously validated imaging rating scale.
The regions evaluated are a anterior cingulate, b orbito-frontal, c anterior temporal, d fronto-insular, e medial temporal and f posterior brain
regions. Statistical significance was considered as p < 0.05
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We further inquired as to which neuropsychological do-
mains could be impaired with the observed atrophy in the
temporal lobe. Indeed, anterior temporal lobe atrophy sig-
nificantly correlated with worse performance on animals
and vegetables naming, i.e., semantic memory/language
domain tests, as also did medial temporal lobe atrophy
with vegetables naming. These findings are consistent
with a previous study that stated the importance of tem-
poral lobe on semantic verbal fluency [2]. Moreover, our
results are consistent with a previous study that showed
predominant anterior hippocampus atrophy on patients
with PART, which also presented semantic memory/lan-
guage domain deficits [20]. Another key point is that, des-
pite using a different brain atrophy assessment
methodology (i.e. visual rating scales), our observations
are somewhat consistent with previous reports using
voxel-based morphometry [20]. Also, we believe our study
provides evidence for the use of a clinical setting-
applicable visual rating scale that can efficiently assess
brain regional atrophy by a trained neuroradiologist. This
could be paramount to routine clinical practice, given the
limited time and resources to continuously post-process
volumetric acquisitions. Since another study found that
semantic memory/language was relatively preserved in
PART compared to AD patients [9], future imaging stud-
ies should tackle the question of potential different pat-
terns of atrophy in PART and AD, and its correlation with
neuropsychological presentation.





































































































































































































p = 0.0530 
r = 0.3836 
p = 0.5885 
r = 0.1113 
p = 0.0677 
r = 0.3638 
p = 0.1013 
r = 0.3285 
p = 0.9429 
r = 0.01476 
p = 0.4570 
r = 0.1525 
Fig. 3 Anterior and Medial temporal lobe atrophy increases with increasing age. The values represented are residuals corrected for Braak staging,
with Pearson correlation analysis between age and atrophy of different brain regions based on a previously validated imaging rating scale. The
regions evaluated are a anterior cingulate, b orbito-frontal, c anterior temporal, d fronto-insular, e medial temporal and f posterior brain regions.
Since statistical significance was considered as p < 0.05, no significant correlations were found, although both anterior temporal (r = 0.3638, p =
0.0677), and medial temporal (r = 0.3836, p = 0.053) regions were found to be close to this statistical threshold
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While this study had some important strengths,
such as the confirmed neuropathologic data and the
usage of an easy to apply and interpret atrophy rating
score, there are some important limitations. First, it
was based on a small, convenience, autopsy-based
sample, a factor that limits its generalizability to other
populations. The NACC database, in general, has lim-
itations of its generalizability, as the participants tend
to be more white and more affluent than the popula-
tion as a whole. However, there was no additional se-
lection bias in choosing the participants for this
study, as we chose all eligible participants (i.e. people
who had neuropathologically defined PART and who
had an MRI available). Second, despite using validated
MRI rating scales on patients with dementia, qualita-
tive assessments and rating are almost invariably asso-
ciated with inter-observer variability. However, given
that observers applying these ratings should have several
years of neuroradiology experience, we believe that in the
clinical setting this could be overcome. Third, despite al-
ways using T1-weighted images on MRI visual rating, not
all were volumetric acquisitions, introducing a source of
variability in this study. Fourth, the variability in scanner
manufacturers and field strengths used on the acquisition
of images is also a potential source of variability in the in-
terpretation and rating of the brain regional atrophy. Fi-
nally, another limitation is that the subset of subjects that
were included in this study had incomplete information
on other co-morbidities that could be associated with
brain atrophy, such as hypertension or diabetes melli-
tus, or on other neuropathologic features, such as
TDP-43 pathology.
Conclusion
In summary, our findings provide evidence that in “def-
inite” PART patients, i.e. brains with tau deposition
without neuritic plaques, there is a correlation between
atrophy of the medial temporal lobe and Braak staging.
Moreover, since we show that aging leads to temporal
lobe atrophy, independently of Braak, other factors
beyond tau tangles could be contributing to atrophy.
Finally, we provide evidence of a potential deficit on
semantic memory/language domain in these patients.
Future studies with volumetric imaging acquisitions
should focus on differences in brain regional atrophy
between PART and AD patients.





































































































p = 0.0056 
r = -0.5823 
p = 0.0019 
r = -0.6371 
p = 0.0435 
r = -0.4445 
Fig. 4 Semantic memory/language impairment correlates with
anterior and medial temporal atrophy. Pearson correlation analysis of
neuropsychological test performance versus temporal brain atrophy
regions evaluated with a previously validated imaging rating scale
for patients with definite PART was performed and only the statistically
significant correlations are shown (p < 0.05). “Vegetables” represents the
number of vegetables a subject can name in 1min. “Animals” represents
the number of animals a subject can name in 1min. a Anterior temporal
lobe atrophy is associated with decreased semantic memory/language,
given by the animals (r =− 0.5823, p = 0.0056) and b vegetables naming
tests (r =− 0.6371, p = 0.0019). c Medial temporal lobe atrophy is also
associated with decreased semantic memory/language, given by the
vegetables naming test (r =− 0.4445, p = 0.0435)
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-019-0842-z.
Additional file 1. Table S1. Atrophy Classification in PART population.
Table S2. Neuropsychological evaluation in PART population. Table S3.
Inter-rater analysis. Figure S1. No asymmetric atrophy observed.
Comparison between right and left hemisphere regional atrophy ratings
was performed. The regions evaluated are a anterior cingulate, b orbito-
frontal, c anterior temporal, d fronto-insular, e medial temporal and f pos-
terior brain regions. Figure S2. No sex differences in atrophy. Comparison
of regional atrophy ratings was performed between men and women
cases. The regions evaluated are a anterior cingulate, b orbito-frontal, c
anterior temporal, d fronto-insular, e medial temporal and f posterior
brain regions. Figure S3. Higher Braak score shows higher atrophy in the
Medial Temporal region. Comparison between cases with Braak ≤ 1 and
Braak ≥ 2. The regions evaluated are a anterior cingulate, b orbito-frontal,
c anterior temporal, d fronto-insular, e medial temporal and f posterior
brain regions. * p < 0.05.
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